76 completed, 40 unknown, 34 terminated, 30 recruiting. 212 Phase 2, 62 Phase 1, 7 Phase 3.
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-28 | 2026-10-27 |
| A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. DXC006, Toripalimab, Carboplatin - Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 200 | 2026-08-19 | 2026-09-24 |
| Tarlatamab for SCLC Brain Metastases Tarlatamab - Small Cell Lung Cancer, Brain Metastases, Adult | Phase 2 | Recruiting | Maastricht University Medical Center | 35 | 2026-08-10 | 2026-10-28 |
| NK Cells Plus ICI for SCLC Maintenance Allogeneic Natural Killer Cells, Immune Checkpoint Inhibitor - Small Cell Lung Cancer | Phase 2 | Recruiting | Tianjin First Central Hospital | 42 | 2026-08-01 | 2026-08-12 |
| QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer QL1706, Anlotinib - Small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 120 | 2026-07-30 | 2026-06-09 |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer PF-08634404, Chemotherapy - Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Pfizer | 40 | 2026-07-02 | 2026-10-09 |
| Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression limertinib, etoposide and carboplatin - Small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 30 | 2026-05-01 | 2026-03-16 |
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC FHD-286 - Small Cell Lung Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 20 | 2026-04-28 | 2026-10-26 |
| Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC Albumin-bound Paclitaxel Combined with Local Therapy, Albumin-Bound Paclitaxel /nab-Paclitaxel - Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 84 | 2026-04-06 | 2026-04-23 |
| SYS6090 Combination Therapy in Advanced Lung Cancer SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel - Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 596 | 2026-02-28 | 2026-03-16 |
| A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer HLX43 dose 1, HLX43 dose 2 - Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Henlius Biotech | 120 | 2026-02-05 | 2026-07-21 |
| Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study Adebrelimab, Oral etoposide soft capsules - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | The Third Affiliated Hospital of Harbin Medical University | 47 | 2026-02-01 | 2026-02-10 |
| SKB500 Combinations in Patients With Small Cell Lung Cancer SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection - Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 80 | 2026-01-30 | 2026-05-08 |
| Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Liposome Irinotecan, Platinum, Anlotinib - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | China Medical University, China | 31 | 2026-01-25 | 2026-01-29 |
| Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) Cirtuvivint, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 42 | 2025-12-18 | 2026-08-12 |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer ABBV-706, Atezolizumab, Etoposide - Small Cell Lung Cancer | Phase 2 | Recruiting | AbbVie | 180 | 2025-11-25 | 2026-10-27 |
| A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors YL201, Ivonescimab - Advanced Solid Tumors, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 260 | 2025-10-29 | 2026-06-18 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide - Small Cell Lung Cancer | Phase 2 | Recruiting | China Medical University, China | 36 | 2025-10-15 | 2026-01-28 |
Showing 20 of 212. Sign in to see all of them.
Small Cell Lung Carcinoma (212) · Carcinoma, Non-Small-Cell Lung (32) · Lung Neoplasms (20) · Breast Neoplasms (13) · Neoplasms (11) · Melanoma (10) · Ovarian Neoplasms (10) · Sarcoma (10) · Carcinoma, Renal Cell (9) · Colorectal Neoplasms (9) · Uterine Cervical Neoplasms (9) · Carcinoma, Hepatocellular (8) · Pancreatic Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (7) · Stomach Neoplasms (7)
Bronchial Neoplasms (212) · Carcinoma, Bronchogenic (212) · Neoplasms by Site (212) · Respiratory Tract Diseases (212) · Respiratory Tract Neoplasms (212) · Lung Diseases (211) · Thoracic Neoplasms (210) · Neoplasms (201) · Lung Neoplasms (192) · Neoplasms by Histologic Type (38) · Neoplasms, Glandular and Epithelial (32) · Carcinoma (27) · Urogenital Diseases (24) · Urogenital Neoplasms (24) · Skin Diseases (22)
Etoposide (29) · Carboplatin (28) · Cisplatin (18) · Topotecan (15) · Irinotecan (13) · Nivolumab (13) · pembrolizumab (11) · durvalumab (10) · Paclitaxel (9) · Drug Therapy (8) · atezolizumab (8) · Bevacizumab (7) · Ipilimumab (7) · anlotinib (7) · Albumin-Bound Paclitaxel (6)
Eli Lilly and Company (6) · Samsung Medical Center (6) · AbbVie (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Fujian Cancer Hospital (3) · G1 Therapeutics, Inc. (3) · Hoosier Cancer Research Network (3) · National Cancer Institute (NCI) (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3) · AHS Cancer Control Alberta (2) · Bristol-Myers Squibb (2) · Celgene (2) · China Medical University, China (2) · Dana-Farber Cancer Institute (2)
United States (92) · China (59) · South Korea (25) · Spain (24) · Italy (21) · France (20) · United Kingdom (17) · Canada (15) · Belgium (14) · Germany (14) · Australia (13) · Netherlands (12) · Poland (12) · Russia (8) · Hungary (7)
Nasser Hanna, M.D. (3) · Anish Thomas, M.D. (2) · David Jackman, MD (2) · Jason Wu (2) · Qiming Wang (2) · Richard S Ungerleider, MD (2) · Thomas Stinchcombe, MD (2)
PMID 34405547, PMID 34408488, PMID 32346071, PMID 33595690, PMID 34589918, PMID 42820295, PMID 12467231, PMID 16170339, PMID 19096313, PMID 19819917, PMID 21102263, PMID 21282543, PMID 21565397, PMID 21633906, PMID 21663862, PMID 22031232, PMID 22722788, PMID 24879333, PMID 25225420, PMID 25616430, PMID 25688059, PMID 25728526, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26200278, PMID 26541586, PMID 26640780, PMID 27133759, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 29119276, PMID 29594044, PMID 30076277, PMID 30137193, PMID 30327308, PMID 30537991, PMID 30641276, PMID 30786188, PMID 31189049, PMID 31504118, PMID 31523058, PMID 31655296, PMID 32250517, PMID 32616557, PMID 32742443, PMID 32897402, PMID 32946924
2016 (3), 2008 (2), 2014 (2), 2015 (2), 2017 (2), 2025 (2), 2004 (1), 2009 (1), 2019 (1), 2023 (1), P30CA015083 (1), R44CA250824 (1)